BRIEF published on 12/17/2025 at 14:43, 2 months 10 days ago First Berlin Equity Research met à jour sa recommandation sur Cardiol Therapeutics, passant à « Acheter » avec un objectif de cours abaissé. Recommandation D'achat Ajustement Du Prix Cible Thérapeutique Cardiaque Étude ARCHER De Phase II Myocardite
BRIEF published on 12/17/2025 at 14:43, 2 months 10 days ago First Berlin Equity Research Updates Cardiol Therapeutics to "Buy" with a Lowered Target Price Buy Recommendation Target Price Adjustment Cardiol Therapeutics Phase II ARCHER Study Myocarditis
PRESS RELEASE published on 12/17/2025 at 14:38, 2 months 10 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., lowering price target to USD 7.80 based on positive Phase II ARCHER data on CardiolRx for acute myocarditis First Berlin Equity Research Buy Recommendation Acute Myocarditis Cardiol Therapeutics Inc. Phase II ARCHER Data
BRIEF published on 10/23/2025 at 12:56, 4 months 4 days ago Cardiol Therapeutics Secures Funding with USD 11.4 Million Private Placement Private Placement Clinical Trials Financial Outlook Cardiol Therapeutics Heart-Failure Therapy
BRIEF published on 10/23/2025 at 12:56, 4 months 4 days ago Cardiol Therapeutics obtient un financement avec un placement privé de 11,4 millions de dollars Placement Privé Essais Cliniques Cardiol Therapeutics Perspectives Financières Traitement De L'insuffisance Cardiaque
PRESS RELEASE published on 10/23/2025 at 12:51, 4 months 4 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates Cardiol Therapeutics Inc with a BUY rating and USD 8.50 price target. The private placement secures funds for pivotal trials and new product development Private Placement Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating USD 8.50 Price Target
BRIEF published on 08/12/2025 at 13:36, 6 months 15 days ago Cardiol Therapeutics : résultats de l'essai de phase II et perspectives boursières positives Cardiol Therapeutics Acheter Une Note CardiolRx Essai ARCHER De Phase II Myocardite Aiguë
BRIEF published on 08/12/2025 at 13:36, 6 months 15 days ago Cardiol Therapeutics: Phase II Trial Results and Positive Stock Outlook BUY Rating Cardiol Therapeutics CardiolRx Phase II ARCHER Trial Acute Myocarditis
PRESS RELEASE published on 08/12/2025 at 13:31, 6 months 15 days ago Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc after positive phase II trial results for CardiolRx in acute myocarditis Cardiol Therapeutics Inc First Berlin Equity Research Phase II Trial CardiolRx Acute Myocarditis
BRIEF published on 04/23/2025 at 15:29, 10 months 4 days ago Cardiol Therapeutics Advances in Pivotal Phase III Study FDA Approval Cardiol Therapeutics Phase III Study Recurrent Pericarditis CardiolRxT
Published on 02/27/2026 at 17:45, 4 hours 13 minutes ago Sparta Capital Ltd. Announces Filing of Annual Financial Statements
Published on 02/27/2026 at 17:41, 4 hours 17 minutes ago Nepra Foods Inc. Achieves First Quarterly Net Income in Company History; Reports Financial Results for the Quarter Ending December 31, 2025, Revenue Increases 51% to $5,973,147, Gross Profit Rises to $1,855,624 (31.1% Margin), Net Income of $84,966
Published on 02/27/2026 at 16:00, 5 hours 58 minutes ago Trans Canada Gold Announces Plans for Exploration and Drilling on its Harrison Lake Gold Project, Lays Out Detailed 2026 Drilling Program Targeting Gold
Published on 02/27/2026 at 14:30, 7 hours 28 minutes ago Solitario Attending PDAC 2026 at Booth 2422A and Participating in One-on-One Meetings
Published on 02/27/2026 at 14:30, 7 hours 28 minutes ago Orogen Royalties Creates a Royalty on the Ecru Gold Project in Nevada, USA
Published on 02/27/2026 at 19:30, 2 hours 28 minutes ago EUROPLASMA: Modification des caractéristiques des tranches 22 et 23 d’OCABSA
Published on 02/27/2026 at 17:59, 3 hours 59 minutes ago EQS-Adhoc: 4finance completes sale of TBI Bank to Advent International
Published on 02/27/2026 at 18:02, 3 hours 55 minutes ago AXA: Execution of a share repurchase agreement in relation to AXAs share buy-back program of up to Euro 1.25 billion
Published on 02/27/2026 at 18:02, 3 hours 55 minutes ago AXA: Conclusion d’une convention de rachat d’actions dans le cadre du programme de rachat d’actions d’AXA
Published on 02/27/2026 at 17:45, 4 hours 13 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of December 31, 2025
Published on 02/27/2026 at 17:45, 4 hours 13 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of January 31, 2026
